Pestalozzi advises 3i and ten23 health in the acquisition of swissfillon  

Ten23 health, a pure-play, patient-centric and sustainable biologics drug product contract development and manufacturing organisation (“CDMO”), backed by 3i Group, has acquired all shares in swissfillon, an FDA and Swissmedic approved drug product-focused CDMO active in the sterile filling of complex pharmaceuticals into innovative containers and devices, such as pre-filled syringes, cartridges and vials. 

The combined business of ten23 health and swissfillon will provide an integrated offering for sterile drug product development and manufacturing of biologics, challenging molecules and dosage forms. swissfillon will continue to operate under its brand, which stands for first-class Swiss quality and excellent know-how. 

Both parties have agreed not to disclose the purchase price. 

Pestalozzi advised 3i Group and its subsidiary ten23 health on all Swiss law aspects of the transaction. The team was included Beat Schwarz (partner – corporate / m&a, pictured), Martin L. Mueller (partner – employment & pensions), Nils Harbeke (partner – tax), Sarah Drukarch (senior associate – life sciences), Raphael Widmer (associate – corporate / m&a),  Andrea P. Rohrer-Lippuner (senior associate – real estate & environment), Florian Schnyder (associate – corporate / m&a), Larissa Rickenbacher (associate – real estate & environment), Hannes F. Baumgartner (associate – corporate / m&a), Martina Herzog (associate – employment), Odette Geldof (junior associate – corporate / m&a).